News Recap for the Week: HNRC, PRSN.V/PRSNF, HALB,
Post# of 35495
https://thestreetreports.com/news-recap-for-t...halb-pcsa/
Successful investors are often known to have a keen idea about the latest happenings in the market, and hence, they stay updated about the news cycle. There are a large number of companies that have been in the news in the past few days, and here is a recap of the news about four of those.
Houston Natural Resources Corporation (OTC:HNRC) The black-check company HNR Acquisition Corp., which had been formed by the oil and gas company, made a major announcement on October 10. Houston Natural announced that it had managed to secure a binding commitment to the tune of $28 million in the form of a secured term loan from Watford City, North Dakota-headquartered First International Bank & Trust (FIBT).
It could be seen as a positive for Houston Natural Resources Corporation as well, and hence, it may be a good time to keep an eye on the stock too. The credit facility would be used to fund a part of the $90 million acquisition of Pogo Resources.
Personas Social Incorporated (OTC SNF) PRSN.V On October 12, the company came into focus after it provided an update on the Keesk Endless Days of Summer Marketing Program. Personas Social Incorporated announced that it had only decided to provide an update for a week of the marketing program since shareholders had made requests for weekly updates.
The company revealed that the first seven days of the program led to around 14000 downloads, which came through the email and social media targeting of legacy users of Keek. It was also noted that the management was happy with the progress and was working on ramping it up.
Halberd Corporation (OTC:HALB) The company was in focus on October 4 after it revealed that the testing results at the Mississippi State University of its proprietary nasal spray meant for mitigating the effects of traumatic brain injury (TBI) had matched the dramatic results of the past.
Halberd Corporation announced at the time that the results were very similar to the earlier proof-of-concept testing that had taken place. The testing revealed a 25% reduction in neuron-specific enolase and a 52.3% reduction in the levels of glial fibrillary acid protein.
Processa Pharmaceuticals Inc. (NASDAQ CSA) is a clinical-stage biotech company involved in the development of advanced chemotherapeutic products meant to improve the safety and effectiveness of cancer treatments.
On October 13, Processa Pharmaceuticals Inc. announced that George NG, its Chief Executive Officer, would make a presentation at the ThinkEquity Conference on October 19, 2023, about the updated company overview. The event would be held at the Mandarin Oriental Hotel in New York, and NG’s presentation would begin at 4:30 eastern time at the Lotus Suite East.